BioCryst Pharmaceuticals | BCRX - 贸易债权人



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 2.09B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


贸易债权人 更改 日
Alnylam Pharmaceuticals USD 108.02M 18.61M 2026-06
BioCryst Pharmaceuticals USD 11.46M 501K 2026-06
Chugai Pharma JPY 160.7B 53.18B 2026-06
Daiichi Sankyo JPY 539.05B 57.81B 2026-06
DBV Technologies USD 39.5M 1.44M 2026-03
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Gilead Sciences USD 645M 70M 2026-03
GlaxoSmithKline GBP 14.34B 7M 2026-06
Glaxosmithkline GBP 14.34B 6.39B 2026-03
Incyte USD 1.39B 1.16B 2026-06
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
Karyopharm Therapeutics USD 4.28M 276K 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Novavax USD 22.94M 6.84M 2026-06
PTC Therapeutics USD 40.45M 14.96M 2026-06
Regeneron Pharmaceuticals USD 1.16B 132.2M 2026-06
Roche Holding CHF 5.54B 237M 2026-06
Sarepta Therapeutics USD 50.98M 19.39M 2026-06
Ultragenyx Pharmaceutical USD 39M 3M 2026-06
Vertex Pharmaceuticals USD 3.61B 135M 2026-06